
    
      A Phase 2b randomized, double-blind, placebo-controlled study of AA4500 in the treatment of
      subjects with Peyronie's disease.

      During the screening period, subjects had a physical examination including body weight and
      height, vital sign measurements, a 12-lead electrocardiogram (ECG), and clinical laboratory
      testing. Medical history, prior and concomitant medications, and demographic data were
      recorded.
    
  